Feb 19, 2026 02:30AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM
Jan 13, 2026 07:00AM
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Dec 22, 2025 02:30AM
Dec 15, 2025 02:30PM
Dec 15, 2025 02:30PM
Dec 15, 2025 09:00AM
Dec 9, 2025 07:01AM
Dec 9, 2025 07:00AM
Oct 30, 2025 09:00PM Daiichi Sankyo begins phase 3 trial of ENHERTU for lung cancer
Oct 30, 2025 09:00PM
Oct 19, 2025 08:45AM
Oct 19, 2025 08:45AM
Oct 19, 2025 02:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Oct 18, 2025 10:30AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 6, 2025 02:30AM
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM
Sep 29, 2025 02:30AM ENHERTU shows significant benefit in HER2-positive early breast cancer trial
Sep 29, 2025 02:30AM
Sep 24, 2025 02:30AM
Sep 15, 2025 07:00AM
Sep 7, 2025 10:45AM
Sep 7, 2025 10:45AM
Aug 18, 2025 07:00AM
Jul 17, 2025 08:00AM ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Jul 9, 2025 08:00AM
Jun 23, 2025 05:05PM
Jun 18, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 2, 2025 08:06AM
Jun 2, 2025 08:00AM
Jun 1, 2025 09:00AM DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
May 31, 2025 08:00AM
May 29, 2025 07:00AM
May 7, 2025 02:30AM
Apr 21, 2025 02:30AM
Mar 31, 2025 08:00AM
Mar 3, 2025 08:00AM
Feb 28, 2025 08:00AM ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Jan 30, 2025 11:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All